We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) upgraded its guidance on Wednesday after it posted growing profit in the third quarter on revenue that beat market expectations.
The British pharmaceutical company made a pretax profit of 1.95 billion pounds ($2.51 billion) in the third quarter, compared with GBP1.71 billion the year earlier. Turnover increased 16% to GBP9.39 billion, beating analyst forecasts of GBP9.04 billion.
Meanwhile adjusted earnings per share--a metric closely watched by analysts--rose to 38.6 pence from 35.5 pence in the third quarter of 2019.
Glaxo said that it is now sees full-year adjusted EPS flat when accounting for currency effects. Previously, the company guided for a decrease of between 3% to 5%.
It confirmed that it was on track to file a new drug application for its cancer drug Zejula by the end of the year having reported positive data from a clinical trial in September that looked at the medicine as a treatment for ovarian cancer.
The company declared a quarterly dividend of 19 pence a share and confirmed its 80 pence total target for the full-year.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com; @carlomartu
(END) Dow Jones Newswires
October 30, 2019 08:37 ET (12:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions